Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Medical System Holdings's revenue for the
six
months ended in Dec. 2025 was $598 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $1,155 Mil.
China Medical System Holdings's Revenue per Share for the
six
months ended in Dec. 2025 was $0.25.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.48.
Warning Sign:
China Medical System Holdings Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of China Medical System Holdings was 14.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -3.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -0.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, China Medical System Holdings's highest 3-Year average Revenue per Share Growth Rate was 32.40% per year. The lowest was -52.80% per year. And the median was 12.80% per year.
China Medical System Holdings (OTCPK:CHSYF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
China Medical System Holdings Revenue Related Terms
China Medical System Holdings Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Medical System Holdings Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where China Medical System Holdings's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,155 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings (CHSYF) has a Revenue of $1,155 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on China Medical System Holdings and its competitors.
Is China Medical System Holdings' Revenue too high?
China Medical System Holdings' current Revenue is $1,155 Mil. Overall, China Medical System Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Medical System Holdings' Revenue compare to ZTS?
China Medical System Holdings' Revenue of $1,155 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on China Medical System Holdings and its competitors. China Medical System Holdings's current Revenue is $1,155 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Medical System Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Medical System Holdings (CHSYF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.30, compared to a current price of $1.57 — trading 20.8% above its estimated fair value. The current Revenue is $1,155 Mil. China Medical System Holdings' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For China Medical System Holdings (CHSYF), the current Revenue is $1,155 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Medical System Holdings (CHSYF) Overvalued in 2026?
Based on GuruFocus' analysis, China Medical System Holdings stock appears to be overvalued.
The current stock price of $1.57 is trading 20.8% above its estimated GF Value™ of $1.30.
GuruFocus considers China Medical System Holdings to be Modestly Overvalued.
Key valuation signals for CHSYF:
Revenue: $1,155 Mil
GF Value™: $1.30 vs. price of $1.57 (20.8% above fair value)
No single metric tells the full story. See the CHSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Medical System Holdings Business Description
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
87GF Score
Get the complete analysis for CHSYF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHSYF has been successfully added to your 
